Physician profile
Stephanie Canham
NPI 1457614729
$4,140.93
in general payments reported to CMS, 2019-2025
32 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $43.29 · 2022: $467 · 2023: $849 · 2024: $1,211 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,082.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $459.06 | 2022-2025 | Ubrelvy |
| Amgen INC. | $441.40 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $432.21 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $358.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $302.97 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $301.57 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.55 | 2019-2025 | Jardiance, Tradjenta |
| Dexcom, INC. | $237.28 | 2022-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $202.29 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $192.01 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $127.67 | 2022-2025 | Eliquis, Camzyos |
| Phathom Pharmaceuticals, INC. | $86.39 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $82.80 | 2023-2024 | Injectafer |
| Abbott Laboratories | $67.89 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $64.63 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $57.90 | 2019-2025 | Opsumit, Uptravi |
| Exact Sciences Corporation | $48.05 | 2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.50 | 2025 | Caplyta |
| Biogen, INC. | $43.33 | 2024 | Skyclarys |
| Boston Scientific Corporation | $39.12 | 2023-2024 | Watchman Flx |
| Glaxosmithkline, LLC. | $33.52 | 2022-2025 | Nucala |
| Biohaven Pharmaceutical Holding Company LTD. | $32.41 | 2022 | |
| Madrigal Pharmaceuticals | $26.29 | 2025 | Rezdiffra |
| Axsome Therapeutics, INC. | $26.10 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $24.34 | 2023 | Gvoke Hypopen |
| Medtronic, INC. | $20.85 | 2023 | Minimed 780g |
| Otsuka America Pharmaceutical, INC. | $18.85 | 2024 | Jynarque |
| Lexicon Pharmaceuticals, INC. | $17.58 | 2024 | |
| Alkermes, INC. | $15.42 | 2025 | Lybalvi |
| Janssen Pharmaceuticals, INC | $15.05 | 2023 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $14.72 | 2023 | Trintellix |
| Grifols USA, LLC | $13.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Canham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.